{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.74","upperLimit":"4.04","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive osimertinib (AZD9291) 80 mg PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.","id":"OG000","title":"Treatment (Osimertinib)"}],"paramType":"MEDIAN","populationDescription":"Eligible, treated and mutation status confirmed","reportingStatus":"POSTED","timeFrame":"Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}